Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR...(sks and uncertainties including butnot l...)

Date:10/24/2008

sks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of its partners are in various stages of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) clinical trials are long, expensive and uncertain processes and the risk of failure of any product that is in clinical development and prior to regulatory approval remains high and can occur at any stage due to efficacy, safety or other factors; (iv) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (v) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit http://www.nektar.com

Stephan Herrera, 415-488-7699

sherrera@nektar.com

Jennifer Ruddock, 6
'/>"/>

SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. BioElectronics Announces Significant Progress in Canadian and International Distribution
2. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
3. Animetrics Inc. Named One of Business NH Magazine's '10 Companies to Watch' for its Significant Revenue Growth
4. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
5. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
6. Phlo Affiliate Announces Significant Distribution Expansion In California
7. On the boil: New nano technique significantly boosts boiling efficiency
8. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources